The Phase 2 obesity study reported outcomes across 1 mg, 4 mg, 8 mg and 12 mg assigned groups. The Phase 3 TRIUMPH-1 paper describes 4 mg, 9 mg and 12 mg research arms.
Assigned research arms
These values identify target amounts used for group comparisons under controlled study protocols. A trial arm combines an assigned intervention, a defined population, scheduled assessments and safety follow-up.
In the Phase 2 paper, the 48-week estimates for the 1 mg, combined 4 mg, combined 8 mg and 12 mg groups were reductions of 8.7%, 17.1%, 22.8% and 24.2%, respectively. Placebo showed a 2.1% reduction. Read these as group averages from a dose-ranging study.
How to interpret the evidence
Use the values to interpret the published tables. Retatrutide remains investigational, and the published arms do not establish a prescribing regimen.
This series reports assigned research arms for interpreting study results. Retatrutide is investigational, and clinical-trial amounts are not dosing instructions.